Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.
暂无分享,去创建一个
L. Pleyer | R. Greil | O. Hantschel | T. Lion | P. Valent | G. Gastl | D. Wolf | K. Geissler | J. Thaler | W. Linkesch | A. Petzer | E. Pittermann | A. Lang